X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13495) 13495
Publication (1681) 1681
Newsletter (499) 499
Book Review (248) 248
Book Chapter (92) 92
Conference Proceeding (41) 41
Newspaper Article (34) 34
Book / eBook (31) 31
Magazine Article (16) 16
Dissertation (12) 12
Reference (8) 8
Transcript (6) 6
Government Document (2) 2
Data Set (1) 1
Paper (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (7284) 7284
humans (6751) 6751
index medicus (6751) 6751
glutamate (6247) 6247
male (5488) 5488
neurosciences (4207) 4207
rats (3346) 3346
pharmacology & pharmacy (3251) 3251
female (3119) 3119
mice (2291) 2291
psychiatry (1683) 1683
adult (1631) 1631
middle aged (1605) 1605
brain (1576) 1576
research (1553) 1553
disease models, animal (1462) 1462
clinical neurology (1416) 1416
neurons (1382) 1382
rats, sprague-dawley (1377) 1377
analysis (1249) 1249
article (1159) 1159
aged (1147) 1147
rodents (1105) 1105
guanine - analogs & derivatives (1068) 1068
glutamates - therapeutic use (1064) 1064
pemetrexed (1059) 1059
treatment outcome (1017) 1017
dose-response relationship, drug (1006) 1006
physiological aspects (999) 999
oncology (986) 986
glutamic acid - metabolism (974) 974
research article (948) 948
health aspects (931) 931
amino acids (926) 926
medicine (924) 924
schizophrenia (901) 901
care and treatment (894) 894
oxidative stress (883) 883
proteins (881) 881
nervous system (880) 880
biochemistry & molecular biology (868) 868
multidisciplinary sciences (867) 867
neurology (849) 849
rats, wistar (832) 832
neuroprotective agents - therapeutic use (824) 824
neuroprotection (822) 822
expression (818) 818
gaba (811) 811
time factors (758) 758
neurons - drug effects (746) 746
metabotropic glutamate receptors (725) 725
brain - metabolism (713) 713
methyl aspartate (712) 712
hippocampus (678) 678
apoptosis (676) 676
science (676) 676
glutamates - administration & dosage (670) 670
neuroscience (668) 668
dopamine (665) 665
pharmacology (643) 643
antineoplastic combined chemotherapy protocols - therapeutic use (634) 634
rat (628) 628
cancer (627) 627
cell biology (624) 624
gene expression (623) 623
glutamate receptors (615) 615
guanine - administration & dosage (615) 615
receptors (615) 615
brain - drug effects (613) 613
neuroprotective agents - pharmacology (611) 611
excitatory amino acid antagonists - pharmacology (608) 608
lung neoplasms - drug therapy (606) 606
drug therapy (594) 594
epilepsy (582) 582
neurons - metabolism (582) 582
cells, cultured (576) 576
mice, inbred c57bl (572) 572
excitatory amino acid antagonists - therapeutic use (570) 570
metabolism (550) 550
glutamic acid (545) 545
activation (544) 544
glutamic acid receptors (543) 543
in-vivo (542) 542
chemotherapy (540) 540
ischemia (535) 535
biology (531) 531
prefrontal cortex (526) 526
guanine - therapeutic use (516) 516
studies (508) 508
long-term potentiation (506) 506
excitotoxicity (502) 502
carcinoma, non-small-cell lung - drug therapy (485) 485
receptors, n-methyl-d-aspartate - metabolism (475) 475
hippocampus - drug effects (470) 470
mental disorders (468) 468
adolescent (466) 466
physiology (466) 466
receptors, n-methyl-d-aspartate - antagonists & inhibitors (461) 461
medical research (456) 456
medicine, research & experimental (454) 454
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13569) 13569
Russian (135) 135
French (101) 101
Japanese (92) 92
German (89) 89
Spanish (44) 44
Chinese (40) 40
Italian (37) 37
Polish (16) 16
Czech (8) 8
Hungarian (7) 7
Portuguese (7) 7
Romanian (4) 4
Turkish (4) 4
Bulgarian (3) 3
Danish (3) 3
Swedish (3) 3
Dutch (2) 2
Korean (2) 2
Hebrew (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Journal Article
2004, ISBN 1402076800, x, 362
Book
Journal of Venomous Animals and Toxins including Tropical Diseases, ISSN 1678-9199, 12/2017, Volume 23, Issue 1, pp. 1 - 12
Abstract Background The N-methyl-D-aspartate (NMDA) receptors are glutamate receptors that play vital roles in central nervous system development and are... 
NR2B | Neurotransmitter | N-methyl-D-aspartate | Antagonists | Glutamate | Synaptic plasticity
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2011, Volume 9, Issue 12, p. CD006165
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article